Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
A single strain of Bacteroides fragilis protects gut integrity and reduces GVHD
M. Hanief Sofi, Yongxia Wu, Taylor Ticer, Steven Schutt, David Bastian, Hee-Jin Choi, Linlu Tian, Corey Mealer, Chen Liu, Caroline Westwater, Kent E. Armeson, Alexander V. Alekseyenko, Xue-Zhong Yu
M. Hanief Sofi, Yongxia Wu, Taylor Ticer, Steven Schutt, David Bastian, Hee-Jin Choi, Linlu Tian, Corey Mealer, Chen Liu, Caroline Westwater, Kent E. Armeson, Alexander V. Alekseyenko, Xue-Zhong Yu
View: Text | PDF
Research Article Immunology Transplantation

A single strain of Bacteroides fragilis protects gut integrity and reduces GVHD

  • Text
  • PDF
Abstract

Graft-versus-host disease (GVHD) is a pathological process caused by an exaggerated donor lymphocyte response to host antigens after allogeneic hematopoietic cell transplantation (allo-HCT). Donor T cells undergo extensive clonal expansion and differentiation, which culminate in damage to recipient target organs. Damage to the gastrointestinal tract is a main contributor to morbidity and mortality. The loss of diversity among intestinal bacteria caused by pretransplant conditioning regimens leads to an outgrowth of opportunistic pathogens and exacerbated GVHD after allo-HCT. Using murine models of allo-HCT, we found that an increase of Bacteroides in the intestinal microbiota of the recipients was associated with reduced GVHD in mice given fecal microbial transplantation. Administration of Bacteroides fragilis through oral gavage increased gut microbiota diversity and beneficial commensal bacteria and significantly ameliorated acute and chronic GVHD development. Preservation of gut integrity following B. fragilis exposure was likely attributed to increased short chain fatty acids, IL-22, and regulatory T cells, which in turn improved gut tight junction integrity and reduced inflammatory cytokine production of pathogenic T cells. The current study provides a proof of concept that a single strain of commensal bacteria can be a safe and effective means to protect gut integrity and ameliorate GVHD after allo-HCT.

Authors

M. Hanief Sofi, Yongxia Wu, Taylor Ticer, Steven Schutt, David Bastian, Hee-Jin Choi, Linlu Tian, Corey Mealer, Chen Liu, Caroline Westwater, Kent E. Armeson, Alexander V. Alekseyenko, Xue-Zhong Yu

×

Figure 1

FMT from Taconic donor mice reduces GVHD.

Options: View larger image (or click on image) Download as PowerPoint
FMT from Taconic donor mice reduces GVHD.
BALB/c or BD2F1 mice were trea...
BALB/c or BD2F1 mice were treated with busulfan at 20 mg/kg and cyclophosphamide at 120 mg/kg daily for 6 days and then injected with 15 × 106/mouse T cell–depleted BM (TCD-BM) alone or plus 15 × 106 total splenocytes for BALB/c and 30 × 106/mouse splenocytes for BD2F1 from normal B6 mice. The bedding of recipient cages was replaced with bedding without (control) or with fecal pellets from Taconic B6 mice. The FMT procedure was done thrice a week starting at 2 weeks prior to BMT and then weekly for a month post-BMT. Recipients were monitored for clinical score (A and C) and survival (B and D) (n = 9–15 per group). Data shown as mean ± SEM were pooled from 2 replicate experiments. Statistical tests: (A and C) 1-way ANOVA, (B and D) log-rank (Mantel-Cox). *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts